Carbocisteine Confers Renoprotection in Streptozotocin‐Induced Diabetic Nephropathy Through Sirt‐1/Nrf‐2‐Dependent Inhibition of NLRP3 Inflammasome Activation
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Omnia A Nour und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Experimental, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Diabetic nephropathy (DN) is a leading cause of end‐stage renal disease, largely driven by oxidative stress and inflammation. This study evaluated the protective role of carbocisteine, a mucolytic with antioxidant and anti‐inflammatory properties, against streptozotocin (STZ)‐induced DN in rats. Male Sprague–Dawley rats were divided into four groups: normal, diabetic, carbocisteine (250 mg/kg), and carbocisteine (500 mg/kg). After 8 weeks, diabetic rats showed significant hyperglycemia, weight loss, renal dysfunction (elevated serum creatinine, BUN, and urinary protein), oxidative stress (increased MDA, decreased GSH), and upregulation of inflammatory mediators; IL‐1β, IL‐6, and TNF‐α, along with downregulation of Sirt‐1 and Nrf‐2 expression and upregulation of NLRP3 and caspase‐1. Moreover, diabetic rats exhibited a pro‐apoptotic shift, characterized by increased Bax and decreased Bcl‐2 expression. Histopathology revealed mesangial expansion, tubular degeneration, and interstitial fibrosis. Carbocisteine treatment, particularly at the high dose, significantly improved renal function, attenuated oxidative and inflammatory responses, restored Sirt‐1 and Nrf‐2 levels, suppressed NLRP3/caspase‐1 activation, and reversed the Bax/Bcl‐2 imbalance, thereby ameliorating histopathological damage. These findings suggest that carbocisteine exerts nephroprotective effects in diabetic rats through modulation of the Sirt‐1/Nrf‐2/NLRP3/caspase‐1 signaling axis and regulation of the Bax/Bcl‐2 apoptotic pathway, highlighting its potential as a promising adjunct therapy for DN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
ORCID-Profile: Omnia A Nour, Mahmoud M Samaha
Zitieren
APA
Nour, O. A., & Samaha, M. M. (2026). Carbocisteine Confers Renoprotection in Streptozotocin‐Induced Diabetic Nephropathy Through Sirt‐1/Nrf‐2‐Dependent Inhibition of NLRP3 Inflammasome Activation. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70356
Vancouver
Nour OA, Samaha MM. Carbocisteine Confers Renoprotection in Streptozotocin‐Induced Diabetic Nephropathy Through Sirt‐1/Nrf‐2‐Dependent Inhibition of NLRP3 Inflammasome Activation. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70356
BibTeX
@article{Nour2026,
author = {Nour, Omnia A and Samaha, Mahmoud M},
title = {Carbocisteine Confers Renoprotection in Streptozotocin‐Induced Diabetic Nephropathy Through Sirt‐1/Nrf‐2‐Dependent Inhibition of NLRP3 Inflammasome Activation},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70356}
}
EUVIMED